18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy.

  title={18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy.},
  author={Xilin Sun and Yongjun Yan and Shuanglong Liu and Qizhen Cao and Min Yang and Nouri Neamati and Baozhong Shen and Gang Niu and Xiaoyuan Chen},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  volume={52 1},
UNLABELLED Abraxane (nanoparticle albumin-bound paclitaxel) is an anticancer drug approved by the Food and Drug Administration. However, the mechanism of action of Abraxane is complex, and no established biomarker is available to accurately monitor its treatment outcomes. The aim of this study was to investigate whether the integrin-specific PET tracer 18F-FPPRGD2 (investigational new drug 104150) can be used to monitor early response of tumors to Abraxane therapy. METHODS Orthotopic MDA-MB… CONTINUE READING